This site is intended for Healthcare Professionals only.

GSK, Pfizer, Sanofi fend off thousands of US lawsuits over alleged Zantac cancer link

Date:

Share post:

Drugmakers GSK, Pfizer, Sanofi and Boehringer Ingelheim on Tuesday were spared thousands of US lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.

The ruling by US District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court, though it does not directly affect tens of thousands of similar cases pending in state courts around the country.

“We are extremely surprised by this miscarriage of justice,” and “fully expect” the ruling will be reversed on appeal, lawyers for the plaintiffs said in a joint statement.

A Sanofi spokesperson said the decision “significantly decreases the scope of the litigation potentially by over 50 per cent,” with the remaining litigation being only in state court.

A spokesperson for GSK said the company welcomed the decision and Pfizer said it was pleased by the outcome.

Privately-held German drugmaker Boehringer said in a statement that it looked forward to “continuing our vigorous defense of the remaining cases in state courts.”

All the drugmakers have denied that Zantac causes cancer.

Zantac, first approved in 1983, became the world’s best selling medicine in 1988 and one of the first-ever drugs to top $1 billion in annual sales. Originally marketed by a forerunner of GSK, it was later sold successively to Pfizer, Boehringer Ingelheim and finally Sanofi.

Numerous generic drugmakers also launched versions of the medicine, but none are defendants in the cases in federal court.

In 2019, some manufacturers and pharmacies halted sales of the drug over concerns that its active ingredient, ranitidine, degraded over time to form a chemical called NDMA. While NDMA is found in low levels in food and water, it is known to cause cancer in larger amounts.

The US Food and Drug Administration in 2020 pulled all remaining brand name Zantac and generic versions off the market, citing research showing the amount of NDMA in the products increases the longer the drug is stored and could potentially become unsafe.

Lawsuits began piling up soon after the recalls began from people who said they developed cancer after taking Zantac. Plaintiffs said the companies knew, or should have known, that ranitidine posed a cancer risk and that they failed to warn consumers.

The litigation initially included claims of over 10 types of cancer allegedly linked to the medicine, but were later narrowed to five – bladder, esophageal, gastrointestinal, liver and pancreatic. Some claims involving other cancers remain in state courts.

All of the cases filed in federal courts nationwide were consolidated before Rosenberg in Florida.

In Tuesday’s order, she found that expert witnesses the plaintiffs planned to use to establish that Zantac can cause cancer could not be admitted in court because they “systemically utilized unreliable methodologies” and showed “a lack of internally consistent, objective, science-based standards for the evenhanded evaluation of data.”

State court judges will also have to rule on whether to allow plaintiffs’ experts on Zantac’s alleged cancer risks before state cases can go to trial.

The legal standards for evaluating experts in many states are similar to the federal standard used by Rosenberg, but state judges could rule differently.

The first state trial is currently scheduled to begin in February in California.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Superdrug to open 25 new high street stores this year

The opening of new Superdrug stores is anticipated to generate over 500 jobs nationwide Superdrug is bolstering its physical...

New Hospital Scheme delays drain millions monthly from ‘scarce’ NHS funds, trust leaders warn

Trust leaders are calling on the next government to commit to constructing 40 new hospitals in England by...

NHS virtual wards set to slash waiting times, prevent 178k admissions in next 2 years

Under the new NHS virtual wards scheme, hospitals to be incentivised for prompt care, with 12-hour A&E target In...

Pharmacist Support: Trainee pharmacists get set to ACTNow for mental health awareness ahead of GPhC assessment

Pharmacist Support's annual mental health awareness campaign offers vital support ahead of GPhC assessment and registration transition Trainee pharmacists...